Integrating Circular RNA & Virus-Like Particle Platforms: Building Analytical & CMC Frameworks for Next-Generation RNA Therapeutics
- Establishing quality and analytical control strategies to support circular RNA–VLP platform development from early R&D through scalable GMP manufacturing
- Characterizing encapsulation efficiency and RNA integrity across distinct delivery modalities to ensure comparability, consistency, and safety
- Designing robust CMC pathways that enable regulatory readiness and streamline technology transfer for novel RNA-based vaccine and therapeutic platforms